SCHEMBL1636700

SCHEMBL1636700

Cc1c(CNC(=O)C2CNC(=O)N2C)cccc1C(F)(F)F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1636112 0.89 P2RX7 (1.00) P2RX7
SCHEMBL1636505 0.88 P2RX7 (1.00) P2RX7
SCHEMBL1637585 0.83 P2RX7 (1.00) P2RX7
SCHEMBL2578453 0.83 P2RX7 (1.00) P2RX7
SCHEMBL1635944 0.83 P2RX7 (1.00) P2RX7
SCHEMBL2578459 0.83 P2RX7 (1.00) P2RX7
SCHEMBL1636545 0.77 P2RX7 (1.00) P2RX7
SCHEMBL1636767 0.76 P2RX7 (1.00) P2RX7
SCHEMBL8013708 0.76 P2RX7 (1.00) P2RX7
SCHEMBL8516206 0.76 P2RX7 (1.00) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932282-B2 Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2011-04-26 US claimed
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators GLAXO GROUP LIMITED (GB) 2010-03-25 US claimed
CN-101679291-A Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LTD 2010-03-24 CN claimed
US-7932282-B2 Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2011-04-26 US disclosed
US-7932282-B2 Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2011-04-26 US disclosed
US-7932282-B2 Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2011-04-26 US disclosed
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
CN-101679291-A Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LTD 2010-03-24 CN disclosed
WO-2008119825-A2 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators P2RX3, P2RX7, P2RX5 P2RX7 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.